WOODRIDGE, Ill., April 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation, today announced it has been invited to make a corporate presentation at the Business Forum of BIO 2006. The Biotechnology Industry Organization’s (BIO) Annual International Convention takes place from April 9-12, 2006 in Chicago, Illinois.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO )
The BIO Business Forum runs simultaneously with the Annual International Convention, and provides a forum for growing biotechnology companies to meet with leaders in the investment, biotechnology and pharmaceutical industries. Executives from Advanced Life Sciences will provide an overview of the Company’s business at 4:00 pm CST on April 11th, in Room B on Level 3 of McCormick Place South Exhibit Hall A.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company’s lead candidate, cethromycin, is a novel ketolide antibiotic in late-stage clinical development for the treatment of respiratory tract infections.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences’ filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Photo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comAdvanced Life Sciences Holdings, Inc.
CONTACT: Investor Relations, Edward P. Flavin of Advanced Life SciencesHoldings, +1-630-739-6744, ext. 211
Web site: http://www.advancedlifesciences.com/
